FOLD News and Press, Amicus Therapeutics Inc. From 02/19/20

CRANBURY, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 2, 2020 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2019. The ca...

Biotech has been one of the big winners of this aging bull market. Over the past 10 years, biotech stocks, on balance, have absolutely clobbered the broader U.S. stock markets. The reason is simple: innovation. Through the advent of game-changing molecular, cellular, and genetic technologies, bi...

CRANBURY, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that one oral presentation and nine posters highligh...

Shares of rare-disease specialist Amicus Therapeutics (NASDAQ: FOLD) are marching higher today. Specifically, the drugmaker's stock is up by 10% as of 12:45 p.m. EST.  What's driving this double-digit rally today? The biotech's shares are jumping in response to a noteworthy upgrade f...

Allakos (NASDAQ: ALLK ) resumed with Neutral rating and $94 (27% upside) at Goldman Sachs. More news on: Incyte Corporation, National Vision Holdings, Inc., Tandem Diabetes Care, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this Read more ...

Amicus Therapeutics (NASDAQ: FOLD ) provides FY 2020 strategic outlook and financial guidance. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Read more ...

2020 Galafold Revenue Guidance of $250M-$260M  Focused on Pompe Phase 3 PROPEL study and manufacturing to support 2021 BLA and MAA Continued Progress Across Industry Leading Rare Disease Gene Therapy Portfolio Strong Balance Sheet with $450M+ Cash – Cash Ru...

Amicus Therapeutics (NASDAQ: FOLD ) announces preliminary 2019 revenue and Galafold (migalastat) commercial updates. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions Galafold Marketing Authorizations Recently Received in Brazil, Colombia and Taiwan Galafold on Track for $500M Revenu...